Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8

1. A method for therapeutically treating a patient, the method comprising administering to the patient a biologically stable, biologically active agonist for TLR8, TLR7 and TLR8, or TLR7, consisting essentially of two single-stranded oligoribonucleotides linked through a 3′-3′ attachment, wherein each of the oligoribonucleotides is 8 to 17 ribonucleotides in length, wherein the sequences of the oligoribonucleotides are identical, and wherein the agonist is not associated with a lipid, condensed with polyethylenimine, or complexed to DOTAP.

2. The method according to claim 1 , wherein the oligoribonucleotides are linked directly to each other at their 3′ ends.

3. The method according to claim 1 , wherein the 3′ ends of the oligoribonucleotides are linked to a non-nucleotidic linker.

4. The method according to claim 3 , wherein the non-nucleotidic linker is an alkyl linker or amino linker, wherein the alkyl or amino linker may be optionally branched or unbranched, cyclic or acyclic, substituted or unsubstituted, saturated or unsaturated, chiral, achiral or racemic mixture.

5. The method according to claim 4 , wherein the alkyl linker has from about 2 to about 18 carbon atoms.

6. The method according to claim 4 , wherein the alkyl linker has from about 3 to about 9 carbon atoms.

7. The method according to claim 4 , wherein the alkyl linker is glycerol, 1,2,4-Butanetriol, 2-Hydroxymethyl-1,3-proanediol, 1,1,1-Tris(hydroxymethyl)ethane, 2-Amino-2-(hydroxymethyl)1,3-propanediol, tris(hydroxymethyl)nitromethane, 1,1,1-Tri(hydroxymethyl)propane, 1,2,6-Hexanetriol, 1,3,5-Hexanetriol, 1,3,5-Pentanetriol, 3-Methyl-1,3,5-pentanetriol, 1,2,3-Heptanetriol, 2-(Hydroxymethyl)1,4-butanediol, 1,3-Di(hydroxymethyl)phenol, 1,3,5-Tri(hydroxymethyl)benzene, 1,3-Di(hydroxyethoxy)-2-hydroxy-propane, 1,3-Di(hydroxypropoxy)-2-hydroxy-propane, D-Galactal, 1,3,5-Tris(2-hydroxyethyl)cyanuric acid or 1,3,5-Tris(4-hydroxyphenyl)benzene.

8. The method according to claim 1 , wherein the oligoribonucleotides comprises modified ribonucleotides.

9. The method according to claim 8 , wherein the modified ribonucleotides are 7-deaza-G, ara-G, 6-thio-G, Inosine, Iso-G, loxoribine, TOG(7-thio-8-oxo)-G, 8-bromo-G, 8-hydroxy-G, 5-aminoformycin B, Oxoformycin, 7-methyl-G, 9-p-chlorophenyl-8-aza-G, 9-phenyl-G, 9-hexyl-guanine, 7-deaza-9-benzyl-G, 6-Chloro-7-deazaguanine, 6-methoxy-7-deazaguanine, 8-Aza-7-deaza-G(PPG), 2-(Dimethylamino)guanosine, 7-Methyl-6-thioguanosine, 8-Benzyloxyguanosine, 9-Deazaguanosine, 9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine, 2-Amino-N2-O—, methyladenosine, 8-Aza-7-deaza-A, 7-deaza-A, Vidarabine, 2-Aminoadenosine, N1-Methyladenosine, 8-Azaadenosine, 5-Iodotubercidin, 1-(B-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine or 4-thio-U, or combinations thereof.

10. The method according to claim 1 , further comprising a 5′ cap.

11. The method according to claim 10 , wherein the 5′ cap is a non-nucleotidic linker.

12. The method according to claim 1 , wherein each of the single-stranded oligoribonucleotides is 8, 9, 10, 11, 14, or 17 ribonucleotides in length.

13. The method according to claim 1 , wherein each of the single-stranded oligoribonucleotides is 11 ribonucleotides in length.

14. The method according to claim 1 , wherein the agonist is:

(a)

5′-UG 1 CUG 1 CUUCUG 1 -X-G 1 UCUUCG 1 UCG 1 U-5′;

(5′-SEQ ID NO: 11-3′-X-3′-SEQ ID NO: 11-5′; SIMRA #11)

(b)

5′-X 2 UGCUGCUUGUG-X-GUGUUCGUCGUX 2 -5′;

(5′- X 2 SEQ ID NO: 30-3′-X-3′-SEQ ID NO: 30X 2 -5′; SIMRA #30)

(c)

5′-X 3 UGCUGCUGCUG-X-GUCGUCGUCGUX 3 -5′;

(5′-X 3 SEQ ID NO: 41-3′-X-3′-SEQ ID NO: 41X 3 -5′; SIMRA #41)

(d)

5′-UG 1 CUG 1 CUUCUG 1 -X 1 -G 1 UCUUCG 1 UCG 1 U-5′;

(5′-SEQ ID NO: 55-3′-X 1 -3′-SEQ ID NO: 55-5′; SIMRA #55)

(e)

5′-UUG 1 CUG 1 UUG 1 CU-X-UCG 1 UUG 1 UCG 1 UU-5′;

(5′-SEQ ID NO: 65-3′-X-3′-SEQ ID NO: 65-5′; SIMRA #65)

(f)

5′-UG 1 CCUUG 1 AACU-X-UCAAG 1 UUCCG 1 U-5′;

(5′-SEQ ID NO: 66-3′-X-3′-SEQ ID NO: 66-5′; SIMRA #66)

(g)

5′-G 1 UCCUUG 1 CUUG 1 -X-G 1 UUCG 1 UUCCUG 1 5′;

(5′-SEQ ID NO: 105-3′-X-3′-SEQ ID NO: 105-5′; SIMRA #105)

(h)

5 ′-X 2 G 1 UCCUUG 1 CUUG 1 -X-G 1 UUCG 1 UUCCUG 1 X 2 -5′;

(5′-X 2 SEQ ID NO: 109-3′-X-3′-SEQ ID NO: 109X 2 -5′; SIMRA #109)

(i)

5′-UG 1 CUG 1 CCUUUG 1 -X-G 1 UUUCCG 1 UCG 1 U-5′;

(5′-SEQ ID NO: 110-3′-X-3′-SEQ ID NO: 110-5′; SIMRA #110) or

(j)

5′-G 1 UCCUUUG 1 CUG 1 -X 9 -G 1 UCG 1 UUUCCUG 1 -5′;

(5′-SEQ ID NO: 113-3′-X 9 -3′-SEQ ID NO: 113-5′; SIMRA #113);

wherein G 1 is 7-deaza-G, X is glycerol, X 2 is a C3 linker or propanediol, X 1 is 1,3,5-pentanetriol, X 3 is a C3 linker or propanediol, X 9 is cis, trans-cyclohexanetriol.

15. The method according to claim 1 , further comprising administering one or more chemotherapeutic compounds or targeted therapeutic agents.

16. The method according to claim 14 , further comprising administering one or more chemotherapeutic compounds or targeted therapeutic agents.

17. The method according to claim 1 , further comprising administering one or more antibodies, vaccines, or antigens.

18. The method according to claim 17 , wherein the vaccine is selected from a DNA vaccine, peptide vaccine, or protein vaccine.

19. The method according to claim 14 , further comprising administering one or more antibodies, vaccines, or antigens.

20. The method according to claim 19 , wherein the vaccine is selected from a DNA vaccine, peptide vaccine, or protein vaccine.